| 1 |
34953094 | Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers. | 2022 Mar 21 |
2 |
| 2 |
32798638 | Controlled loading of albumin-drug conjugates ex vivo for enhanced drug delivery and antitumor efficacy. | 2020 Dec 10 |
1 |
| 3 |
31184188 | Preparation of a Multiple-Targeting NIR-Based Fluorogenic Probe and Its Application for Selective Cancer Cell Imaging. | 2019 Jun 21 |
1 |
| 4 |
29473076 | Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates. | 2018 Mar 14 |
1 |
| 5 |
31156276 | Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research. | 2018 Oct 3 |
1 |
| 6 |
29123088 | A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. | 2017 Nov 9 |
2 |
| 7 |
23903896 | Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin. | 2014 Feb |
1 |
| 8 |
23712251 | Toward very potent, non-covalent organophosphonate inhibitors of cathepsin C and related enzymes by 2-amino-1-hydroxy-alkanephosphonates dipeptides. | 2013 Aug |
1 |
| 9 |
24900316 | Design, Synthesis, and Antitumor Activity of 4-Halocolchicines and Their Pro-drugs Activated by Cathepsin B. | 2011 May 12 |
1 |
| 10 |
19131246 | Development of dual-acting prodrugs for circumventing multidrug resistance. | 2009 Feb 1 |
1 |
| 11 |
19199576 | Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs. | 2009 Feb |
1 |
| 12 |
11802791 | S2' substrate specificity and the role of His110 and His111 in the exopeptidase activity of human cathepsin B. | 2002 Feb 1 |
2 |
| 13 |
12121142 | Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. | 2002 Jul-Aug |
1 |
| 14 |
10841792 | Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. | 2000 Jun 1 |
1 |
| 15 |
9873731 | Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. | 1998 Dec 1 |
1 |
| 16 |
9873732 | Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. | 1998 Dec 1 |
2 |
| 17 |
8754751 | The combined action of two thyroidal proteases releases T4 from the dominant hormone-forming site of thyroglobulin. | 1996 Aug |
2 |
| 18 |
8230139 | Peptide alpha-keto ester, alpha-keto amide, and alpha-keto acid inhibitors of calpains and other cysteine proteases. | 1993 Oct 29 |
1 |
| 19 |
1797709 | Synthesis of histidine-containing dipeptide affinity-labelling agents. Relative inactivation rates of cathepsins B and L. | 1991 Oct |
1 |
| 20 |
3318115 | [Brain cathepsin as dipeptidylcarboxypeptidase transforming provasopressor, pro-opioid and model peptides]. | 1987 Sep-Oct |
2 |
| 21 |
666735 | The specificity of cathepsin B. Hydrolysis of glucagon at the C-terminus by a peptidyldipeptidase mechanism. | 1978 Jun 1 |
1 |